## FORM 4

obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
abligations may continue Cos	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MCENANY PATRICK J					2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICAL									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
MCENANY PAIRICK J					PARTNERS, INC. [ CPRX ]									X	Direc	ctor		10% C	wner	
(Last)	(Fi	rst) (	Middle)												X	Office belov	er (give title v)		Other below)	(specify
355 ALHAMBRA CIRCLE, SUITE 1500					3. Date of Earliest Transaction (Month/Day/Year) 04/27/2015									President and CEO						
(Street)	. FL	. 3	3134		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
GABLES 33134															Form filed by More than One Reporting Person					
(City)	(St	ate) (	Zip)													Pers	OH			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date		n Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Secur Benet		cially I Following	Form: (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	•	Transaction(s) (Instr. 3 and 4)				(11150.4)
Common stock, par value \$0.001 per share 04/27				04/27	//2015			P		5,000	)	A	\$3.	3.79 4,1		4,127,262		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n of		6. Date E Expiratio (Month/D	е	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			Deri Seci	ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisa		Expiration Date	Titl	or Nur of	nber						

**Explanation of Responses:** 

/s/ Patrick J. McEnany

04/27/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.